Xspray Pharma publishes its annual report for 2020

Regulatory press release 2021-03-19

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the company's annual report for the financial year 2020 has been published.

“Our HyNap technology is the first of its kind in the world and allows multiple pathways to success. During the year, we established a unique supply chain and strengthened the patent position concurrently with continued development of our first product candidate. I am therefore confident, that in 2021 we are well positioned to drive forward development of our pipeline product candidates with early entry dates and for which patent windows enable an advantageous US market launch.

Although we suffered a delay in the development of our first generic product candidate HyNap-Dasa, we could use the study results to expand the product portfolio with an improved version of the product. As a result, we now have two HyNap-Dasa product candidates, a generic version intended for the US market and an improved version for the worldwide market. Coupled with the progress of the HyNap-Nilo project, it demonstrates the usefulness of our strategy and the technology platform in creating multiple pathways to success,” says Per Andersson, CEO Xspray Pharma.

The annual report is attached and can also be downloaded from the company's website, www.xspraypharma.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharma company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 55 in December 2020. The company’s leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed in two versions, a generic and an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com